Tag: SAB-185
SAB Biotherapeutics awarded $57.5 to manufacture its therapeutic candidate for COVID-19
Clinical stage biopharma company SAB Biotherapeutics has been awarded $57.5 million from BARDA and the US Department of Defence for the manufacturing of SAB-185,...
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
